Faron Historical Income Statement

FARN Stock

165.00 10.00 5.71%

Historical analysis of Faron Pharmaceuticals income statement accounts such as Selling General Administrative of 9.1 M or Other Operating Expenses of 15.5 M can show how well Faron Pharmaceuticals Oy performed in making a profits. Evaluating Faron Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Faron Pharmaceuticals's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Faron Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Faron Pharmaceuticals is a good buy for the upcoming year.

Net Income Gross Profit

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Faron Pharmaceuticals Oy. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Faron Income Statement Analysis

Faron Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Faron Pharmaceuticals shareholders. The income statement also shows Faron investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Faron Pharmaceuticals Income Statement Chart

At this time, Faron Pharmaceuticals' Interest Expense is comparatively stable compared to the past year. Selling General Administrative is likely to gain to about 9.1 M in 2024, whereas Other Operating Expenses is likely to drop slightly above 15.5 M in 2024.

Selling General Administrative Research Development Net Interest Income

Net Interest Income

The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.

Most accounts from Faron Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Faron Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Faron Pharmaceuticals Oy. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2021	2022	2023	2024 (projected)
Interest Expense	235K	1.4M	2.2M	2.3M
Depreciation And Amortization	306K	300K	197K	185.2K

Interest Expense Depreciation And Amortization

Faron Pharmaceuticals income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Gross Profit	Net Income From Continuing Ops	Tax Provision	Net Interest Income	Interest Income	Reconciled Depreciation	Selling And Marketing Expenses
Depreciation And Amortization		0.41	0.78	0.68	-0.65	-0.65	0.64	-0.65	0.68	-0.64	-0.31	-0.65	0.32	-0.11	-0.65	-0.6	-0.39	-0.82	0.84	-0.14
Interest Expense	0.41		0.75	0.61	-0.75	-0.75	0.52	-0.75	0.61	-0.78	-0.98	-0.78	0.97	-0.3	-0.77	-0.59	-1.0	-0.42	0.72	-0.85
Selling General Administrative	0.78	0.75		0.84	-0.9	-0.9	0.8	-0.9	0.84	-0.91	-0.68	-0.9	0.65	-0.32	-0.91	-0.78	-0.75	-0.75	0.88	-0.57
Other Operating Expenses	0.68	0.61	0.84		-0.96	-0.96	0.99	-0.96	1.0	-0.95	-0.56	-0.95	0.52	-0.35	-0.95	-0.9	-0.61	-0.67	0.76	-0.29
Operating Income	-0.65	-0.75	-0.9	-0.96		1.0	-0.94	1.0	-0.96	1.0	0.7	1.0	-0.66	0.4	1.0	0.93	0.74	0.69	-0.78	0.53
Ebit	-0.65	-0.75	-0.9	-0.96	1.0		-0.94	1.0	-0.96	1.0	0.7	1.0	-0.66	0.38	1.0	0.93	0.74	0.69	-0.78	0.53
Research Development	0.64	0.52	0.8	0.99	-0.94	-0.94		-0.94	0.99	-0.93	-0.48	-0.93	0.44	-0.34	-0.93	-0.91	-0.53	-0.66	0.7	-0.24
Ebitda	-0.65	-0.75	-0.9	-0.96	1.0	1.0	-0.94		-0.96	1.0	0.7	1.0	-0.66	0.38	1.0	0.93	0.74	0.69	-0.78	0.53
Total Operating Expenses	0.68	0.61	0.84	1.0	-0.96	-0.96	0.99	-0.96		-0.95	-0.56	-0.95	0.52	-0.35	-0.95	-0.9	-0.61	-0.67	0.76	-0.29
Income Before Tax	-0.64	-0.78	-0.91	-0.95	1.0	1.0	-0.93	1.0	-0.95		0.73	1.0	-0.69	0.39	1.0	0.92	0.78	0.68	-0.79	0.56
Total Other Income Expense Net	-0.31	-0.98	-0.68	-0.56	0.7	0.7	-0.48	0.7	-0.56	0.73		0.73	-0.96	0.2	0.73	0.51	0.98	0.25	-0.61	0.86
Net Income	-0.65	-0.78	-0.9	-0.95	1.0	1.0	-0.93	1.0	-0.95	1.0	0.73		-0.7	0.39	1.0	0.92	0.78	0.68	-0.79	0.55
Income Tax Expense	0.32	0.97	0.65	0.52	-0.66	-0.66	0.44	-0.66	0.52	-0.69	-0.96	-0.7		-0.26	-0.69	-0.47	-0.97	-0.31	0.61	-0.79
Gross Profit	-0.11	-0.3	-0.32	-0.35	0.4	0.38	-0.34	0.38	-0.35	0.39	0.2	0.39	-0.26		0.38	0.57	0.3	0.44	-0.43	0.2
Net Income From Continuing Ops	-0.65	-0.77	-0.91	-0.95	1.0	1.0	-0.93	1.0	-0.95	1.0	0.73	1.0	-0.69	0.38		0.92	0.77	0.68	-0.79	0.56
Tax Provision	-0.6	-0.59	-0.78	-0.9	0.93	0.93	-0.91	0.93	-0.9	0.92	0.51	0.92	-0.47	0.57	0.92		0.58	0.74	-0.74	0.4
Net Interest Income	-0.39	-1.0	-0.75	-0.61	0.74	0.74	-0.53	0.74	-0.61	0.78	0.98	0.78	-0.97	0.3	0.77	0.58		0.38	-0.71	0.85
Interest Income	-0.82	-0.42	-0.75	-0.67	0.69	0.69	-0.66	0.69	-0.67	0.68	0.25	0.68	-0.31	0.44	0.68	0.74	0.38		-0.81	0.19
Reconciled Depreciation	0.84	0.72	0.88	0.76	-0.78	-0.78	0.7	-0.78	0.76	-0.79	-0.61	-0.79	0.61	-0.43	-0.79	-0.74	-0.71	-0.81		-0.44
Selling And Marketing Expenses	-0.14	-0.85	-0.57	-0.29	0.53	0.53	-0.24	0.53	-0.29	0.56	0.86	0.55	-0.79	0.2	0.56	0.4	0.85	0.19	-0.44

Click cells to compare fundamentals

Faron Pharmaceuticals Account Relationship Matchups

Faron Pharmaceuticals income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	238K	283K	306K	300K	197K	185.2K
Interest Expense	224K	389K	235K	1.4M	2.2M	2.3M
Selling General Administrative	3.0M	4.9M	9.9M	7.5M	8.7M	9.1M
Other Operating Expenses	13.1M	16.7M	21.1M	27.4M	28.6M	15.5M
Operating Income	(13.1M)	(16.7M)	(21.1M)	(27.4M)	(28.6M)	(27.1M)
Ebit	(13.0M)	(16.8M)	(21.0M)	(27.4M)	(28.6M)	(27.1M)
Research Development	10.2M	13.9M	17.4M	20.7M	19.5M	12.5M
Ebitda	(12.8M)	(16.5M)	(20.7M)	(27.1M)	(28.4M)	(27.0M)
Total Operating Expenses	13.1M	16.7M	21.1M	27.4M	28.6M	15.5M
Income Before Tax	(13.3M)	(16.9M)	(21.2M)	(28.7M)	(30.9M)	(29.4M)
Total Other Income Expense Net	(150K)	(280K)	(70K)	(1.3M)	(2.4M)	(2.3M)
Net Income	(13.3M)	(16.9M)	(21.2M)	(30.0M)	(30.9M)	(29.4M)
Income Tax Expense	11K	10K	16K	1.3M	1.5M	1.6M
Net Income From Continuing Ops	(13.3M)	(16.9M)	(21.2M)	(28.7M)	(30.9M)	(29.4M)
Net Income Applicable To Common Shares	(13.3M)	(16.9M)	(21.2M)	(28.7M)	(25.9M)	(24.6M)
Tax Provision	1K	2K	11K	10K	16K	0.0
Net Interest Income	(158K)	(282K)	(245K)	(1.3M)	(2.4M)	(2.3M)
Interest Income	148K	9K	2K	11K	230K	125K
Reconciled Depreciation	238K	283K	307K	300K	346K	259.3K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Faron Stock Analysis

When running Faron Pharmaceuticals' price analysis, check to measure Faron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Faron Pharmaceuticals is operating at the current time. Most of Faron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Faron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Faron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Faron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Faron Historical Income Statement

About Faron Income Statement Analysis

Faron Pharmaceuticals Income Statement Chart

Net Interest Income

Faron Pharmaceuticals income statement Correlations

Faron Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Faron Pharmaceuticals income statement Accounts

Also Currently Popular

Additional Tools for Faron Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income
Net Income	+ 1.0	Operating Income
Net Income From Continuing Ops	+ 1.0	Operating Income

Net Interest Income	- 1.0	Interest Expense
Total Other Income Expense Net	- 0.98	Interest Expense
Net Interest Income	- 0.97	Income Tax Expense
Income Tax Expense	- 0.96	Total Other Income Expense Net
Total Operating Expenses	- 0.96	Ebitda
Total Operating Expenses	- 0.96	Ebit